RxDoctor Payments Data

David Krueger, MD

Physical Medicine & Rehabilitation · Naples, FLNPI 1730294620

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 436 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,194, 2.1 times the $1,040 reported in 2019. Among physical medicine & rehabilitation clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,786in general payments, 2019–2025

Across 436 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • AstraZeneca$904
  • AbbVie$509
  • Amgen$466
  • Lilly USA, LLC$406
  • Teva Pharmaceuticals USA, Inc.$388
  • plus $6K from 52 others

What the payments were for

  • Speaking & faculty fees$1171%
  • Food & beverage$9,66999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.40$1,149
AstraZeneca(2 entities)28$904
AbbVie31$509
Amgen(2 entities)23$466
Lilly USA, LLC26$406
Teva Pharmaceuticals USA, Inc.19$388
GE HealthCare23$382
Eisai Inc.14$351
Abbott3$338
Neurocrine Biosciences, Inc.12$329
Acadia Pharmaceuticals Inc15$292
Neurelis, Inc.17$290
Amneal Pharmaceuticals LLC15$271
Merz Pharmaceuticals, LLC10$256
Novartis20$237
Acorda Therapeutics, Inc8$199
Lundbeck LLC8$193
Avanir Pharmaceuticals, Inc.11$192
Biogen4$183
Johnson & Johnson(2 entities)12$180
Medtronic(2 entities)3$163
Sanofi6$146
Merz North America, Inc.6$133
Biodelivery Sciences International, Inc.1$125
Scilex Pharmaceuticals Inc.5$118
Pfizer6$118
Kyowa Kirin, Inc.6$115
Biohaven Pharmaceutical Holding Company Ltd.5$106
Bristol Myers Squibb5$104
Argenx US, Inc.5$102
Biohaven Pharmaceuticals, Inc.4$88
MDD US Operations, LLC4$81
E.r. Squibb & Sons, L.L.C.4$73
Sumitomo Pharma America, Inc.3$72
SK Life Science, Inc.2$68
Adamas Pharmaceuticals, Inc.3$47
Tanabe Pharma America, Inc.3$47
Azurity Pharmaceuticals, Inc.2$44
Vanda Pharmaceuticals Inc.2$44
Xeris Pharmaceuticals, Inc.2$43
Takeda Pharmaceuticals U.S.A., Inc.1$35
Averitas Pharma Inc.1$34
Almatica Pharma LLC2$34
Sunovion Pharmaceuticals Inc.2$32
Mallinckrodt Hospital Products Inc.1$32
Novocure Inc.1$29
Octapharma USA, Inc.1$26
Collegium Pharmaceutical, Inc.1$25
Boston Scientific1$23
Catalyst Pharmaceuticals, Inc.1$21
Aprecia Pharmaceuticals, LLC1$21
Banner Life Sciences, LLC1$20
TG Therapeutics, Inc.1$19
Nevro Corp.1$19
Otsuka America Pharmaceutical, Inc.1$17
Livanova USA, Inc.1$17
Upsher-smith Laboratories LLC1$16
Cala Health, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,786 in reported general payments places this provider in the 95th percentile of 618 physical medicine & rehabilitation providers in Florida.

See all physical medicine & rehabilitation providers in Florida

Medicare billing

Part B allowed, 2024
$477,629
Medicare patients
840
Services billed
7,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl19$17,635
Buprenorphine48$8,473
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen216$8,210
Xtampza ErOxycodone Myristate18$7,550
Gabapentin464$7,299
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl58$5,918
Duloxetine Hcl219$5,420
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen168$4,449
Pregabalin184$4,180
Fentanyl29$2,611
Tramadol Hcl276$2,204
Tizanidine Hcl143$2,191
Meloxicam304$1,197
Levetiracetam45$999
Cyclobenzaprine Hcl33$995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$25$7,55018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 physical medicine & rehabilitation providers in Florida.

Other physical medicine & rehabilitation in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →